Drugs / abiraterone decanoate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04729114 | Jun 2021 → May 2029 expected | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | abiraterone decanoate | “abiraterone decanoate for intramuscular injection” NCT04729114 ↗ |
| Known as | Prl-02 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314964 ↗ |
| Modality | Small molecule | — CHEMBL5314964 ↗ |